No Benefit to Using Omeprazole or PPIs in Dengue
There is no established benefit to using omeprazole or other proton pump inhibitors (PPIs) in patients with dengue, and they should not be routinely prescribed for this indication. Dengue management is entirely supportive, focused on judicious fluid resuscitation during the critical phase, and there is no role for acid suppression therapy unless a separate, specific gastrointestinal indication exists 1.
Why PPIs Are Not Indicated in Dengue
The evidence is clear on dengue management: no definitive curative medications exist for dengue; management is supportive 1. The cornerstone of treatment involves:
- Careful fluid resuscitation with crystalloids during the critical phase
- Monitoring for plasma leakage, severe bleeding, and organ impairment
- Recognition and management of complications like secondary hemophagocytic lymphohistiocytosis
PPIs have no mechanism of action that would benefit the pathophysiology of dengue infection, which involves viral replication, immune response, plasma leakage, and potential hemorrhagic complications. Acid suppression does not address any of these disease processes.
When PPIs Might Be Considered (Separate Indications Only)
PPIs should only be used in dengue patients if they have a separate, definitive indication unrelated to dengue itself 2:
- Active peptic ulcer disease (duodenal or gastric ulcers requiring healing)
- Severe erosive esophagitis (LA Classification grade C/D)
- Gastroprotection in patients requiring NSAIDs/aspirin who are at high risk for GI bleeding
- Active upper GI bleeding from peptic ulcer disease
These indications are based on FDA-approved uses 2 and should follow standard treatment durations (typically 4-8 weeks for acute conditions).
Important Caveats About PPI Use
If a dengue patient happens to require a PPI for a legitimate separate indication, be aware of significant risks with use:
- Increased risk of severe diarrhea from Clostridium difficile infection 2
- Kidney problems (tubulointerstitial nephritis) that can occur at any time 2
- Bone fractures with long-term use (hip, wrist, spine) 2
- Drug interactions particularly with antiretrovirals, warfarin, clopidogrel, and methotrexate 2
Use the lowest effective dose for the shortest duration necessary 2. This is particularly important given that approximately 63% of PPI users receive high doses (≥ defined daily dose), and 25% continue therapy beyond 1 year, often inappropriately 3.
Common Pitfall to Avoid
Do not prescribe PPIs empirically in dengue patients based on vague concerns about "gastric protection" or "stress ulcer prophylaxis." Stress ulcer prophylaxis is only indicated for high-risk critically ill patients in the ICU setting 4, not for routine dengue management. The widespread inappropriate use of PPIs—particularly continuation after hospital discharge—is a well-documented problem 4, 3.
If a dengue patient is already on a PPI without a clear ongoing indication, this is an opportunity to deprescribe 5. Most patients without a definitive indication for chronic PPI use should be considered for trial of discontinuation 5.